Journal of Clinical Oncology, Vol 18, Issue 3
(February), 2000: 636
© 2000 American Society for Clinical Oncology
Alterations of Chromosome Arms 1p and 19q as Predictors of Survival in Oligodendrogliomas, Astrocytomas, and Mixed Oligoastrocytomas
By Justin S. Smith,
Arie Perry,
Thomas J. Borell,
Hyun K. Lee,
Judith OFallon,
Sandra M. Hosek,
David Kimmel,
Allan Yates,
Peter C. Burger,
Bernd W. Scheithauer,
Robert B. Jenkins
From the Division of Laboratory Genetics, Division of Anatomic Pathology, Department of Neurology, and Section of Biostatistics, Mayo Clinic and Foundation, Rochester, MN; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; Division of Neuropathology, Ohio State University, Columbus, OH; and Washington University School of Medicine, St Louis, MO.
Address reprint requests to Robert B. Jenkins, MD, PhD, Department of Cytogenetics, Mayo Clinic, 200 First St, Southwest, Rochester, MN 55905; email rjenkins{at}mayo.edu
PURPOSE: A recent report suggests that alterations of chromosome arms 1p and 19q are associated with chemotherapeutic response and overall survival in anaplastic oligodendroglioma patients treated with procarbazine, lomustine, and vincristine chemotherapy. We set out to further clarify the diagnostic and prognostic implications of these alterations in a broader set of diffuse gliomas, including astrocytic neoplasms and low-grade oligodendrogliomas.
PATIENTS AND METHODS: Fluorescence in situ hybridization (FISH) signals from DNA probes mapping to 1p and 19q common deletion regions were enumerated in 162 diffuse gliomas (79 astrocytomas, 52 oligodendrogliomas, and 31 mixed oligoastrocytomas), collected as part of an ongoing prospective investigation of CNS tumors.
RESULTS: The oligodendroglial phenotype was highly associated with loss of 1p (P = .0002), loss of 19q (P < .0001), and combined loss of 1p and 19q (P < .0001). Combined loss of 1p and 19q was identified as a univariate predictor of prolonged overall survival among patients with pure oligodendroglioma (log-rank, P = .03) and remained a significant predictor after adjusting for the effects of patient age and tumor grade (P < .01). This favorable association was not evident in patients with astrocytoma or mixed oligoastrocytoma.
CONCLUSION: Combined loss of 1p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade. Given the lack of this association in patients with astrocytic neoplasms and the previously demonstrated chemosensitivity of oligodendrogliomas, a combined approach of histologic and genotypic assessment could potentially improve existing strategies for patient stratification and management.
The first two authors contributed equally to this study.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Snuderl, A. F. Eichler, K. L. Ligon, Q. U. Vu, M. Silver, R. A. Betensky, A. H. Ligon, P. Y. Wen, D. N. Louis, and A. J. Iafrate
Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss
Clin. Cancer Res.,
October 15, 2009;
15(20):
6430 - 6437.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Mahajan and R. A. Prayson
Repeated Molecular Testing in Gliomas: A Retrospective Study of 53 Cases
Am J Clin Pathol,
July 1, 2009;
132(1):
118 - 124.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. C. Bromberg and M. J. van den Bent
Oligodendrogliomas: Molecular Biology and Treatment
Oncologist,
February 1, 2009;
14(2):
155 - 163.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Liu, K. Solheim, M.-Y. Polley, K. R. Lamborn, M. Page, A. Fedoroff, J. Rabbitt, N. Butowski, M. Prados, and S. M. Chang
Quality of life in low-grade glioma patients receiving temozolomide
Neuro-oncol,
January 1, 2009;
11(1):
59 - 68.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Vogelbaum, B. Berkey, D. Peereboom, D. Macdonald, C. Giannini, J. H. Suh, R. Jenkins, J. Herman, P. Brown, D. T. Blumenthal, et al.
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131
Neuro-oncol,
January 1, 2009;
11(2):
167 - 175.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. H. Hartel, A. L. Shackelford, J. V. Hartel, and S. L. Wenger
Del(5q) Is Associated With Clinical and Histological Parameters in Small Cell Neuroendocrine Lung Carcinoma
International Journal of Surgical Pathology,
October 1, 2008;
16(4):
419 - 423.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
K.E. Emblem, D. Scheie, P. Due-Tonnessen, B. Nedregaard, T. Nome, J.K. Hald, K. Beiske, T.R. Meling, and A. Bjornerud
Histogram Analysis of MR Imaging-Derived Cerebral Blood Volume Maps: Combined Glioma Grading and Identification of Low-Grade Oligodendroglial Subtypes
AJNR Am. J. Neuroradiol.,
October 1, 2008;
29(9):
1664 - 1670.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Brown, M. Zlatescu, A. Sijben, G. Roldan, J. Easaw, P. Forsyth, I. Parney, R. Sevick, E. Yan, D. Demetrick, et al.
The Use of Magnetic Resonance Imaging to Noninvasively Detect Genetic Signatures in Oligodendroglioma
Clin. Cancer Res.,
April 15, 2008;
14(8):
2357 - 2362.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Wohlfahrt, B. C. Beard, A. Lieber, and H.-P. Kiem
A Capsid-Modified, Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL Leads to Enhanced Cancer Cell Killing in Human Glioblastoma Models
Cancer Res.,
September 15, 2007;
67(18):
8783 - 8790.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. E. Abrey, D. N. Louis, N. Paleologos, A. B. Lassman, J. J. Raizer, W. Mason, J. Finlay, D. R. MacDonald, L. M. DeAngelis, J. G. Cairncross, et al.
Survey of treatment recommendations for anaplastic oligodendroglioma
Neuro-oncol,
July 1, 2007;
9(3):
314 - 318.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Hong, K. S. Moorefield, P. Jun, K. D. Aldape, S. Kharbanda, H. S. Phillips, and J. F. Costello
Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth
PNAS,
June 26, 2007;
104(26):
10974 - 10979.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Lavon, D. Zrihan, B. Zelikovitch, Y. Fellig, D. Fuchs, D. Soffer, and T. Siegal
Longitudinal Assessment of Genetic and Epigenetic Markers in Oligodendrogliomas
Clin. Cancer Res.,
March 1, 2007;
13(5):
1429 - 1437.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. R. Miller, C. P. Dunham, B. W. Scheithauer, and A. Perry
Significance of Necrosis in Grading of Oligodendroglial Neoplasms: A Clinicopathologic and Genetic Study of Newly Diagnosed High-Grade Gliomas
J. Clin. Oncol.,
December 1, 2006;
24(34):
5419 - 5426.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Okahara, K. Itoh, A. Nakagawara, M. Murakami, Y. Kanaho, and T. Maehama
Critical Role of PICT-1, a Tumor Suppressor Candidate, in Phosphatidylinositol 3,4,5-Trisphosphate Signals and Tumorigenic Transformation
Mol. Biol. Cell,
November 1, 2006;
17(11):
4888 - 4895.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. B. Jenkins, H. Blair, K. V. Ballman, C. Giannini, R. M. Arusell, M. Law, H. Flynn, S. Passe, S. Felten, P. D. Brown, et al.
A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma.
Cancer Res.,
October 15, 2006;
66(20):
9852 - 9861.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Brandes, A. Tosoni, G. Cavallo, M. Reni, E. Franceschi, L. Bonaldi, R. Bertorelle, M. Gardiman, C. Ghimenton, P. Iuzzolino, et al.
Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study
J. Clin. Oncol.,
October 10, 2006;
24(29):
4746 - 4753.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Mariani, G. Deiana, E. Vassella, A.-R. Fathi, C. Murtin, M. Arnold, I. Vajtai, J. Weis, P. Siegenthaler, M. Schobesberger, et al.
Loss of Heterozygosity 1p36 and 19q13 Is a Prognostic Factor for Overall Survival in Patients With Diffuse WHO Grade 2 Gliomas Treated Without Chemotherapy
J. Clin. Oncol.,
October 10, 2006;
24(29):
4758 - 4763.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Jeuken, S. Cornelissen, S. Boots-Sprenger, S. Gijsen, and P. Wesseling
Multiplex Ligation-Dependent Probe Amplification: A Diagnostic Tool for Simultaneous Identification of Different Genetic Markers in Glial Tumors
J. Mol. Diagn.,
September 1, 2006;
8(4):
433 - 443.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Engler, G. Mohapatra, D. N. Louis, and R. A. Betensky
A pseudolikelihood approach for simultaneous analysis of array comparative genomic hybridizations
Biostat.,
July 1, 2006;
7(3):
399 - 421.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Jenkinson, D. G. du Plessis, T. S. Smith, K. A. Joyce, P. C. Warnke, and C. Walker
Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features
Brain,
July 1, 2006;
129(7):
1884 - 1891.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Cairncross, B. Berkey, E. Shaw, R. Jenkins, B. Scheithauer, D. Brachman, J. Buckner, K. Fink, L. Souhami, N. Laperierre, et al.
Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
J. Clin. Oncol.,
June 20, 2006;
24(18):
2707 - 2714.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. van den Bent, A. F. Carpentier, A. A. Brandes, M. Sanson, M. J.B. Taphoorn, H. J.J.A. Bernsen, M. Frenay, C. C. Tijssen, W. Grisold, L. Sipos, et al.
Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
J. Clin. Oncol.,
June 20, 2006;
24(18):
2715 - 2722.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Walker, B. Haylock, D. Husband, K. A. Joyce, D. Fildes, M. D. Jenkinson, T. Smith, J. Broome, D. G. du Plessis, and P. C. Warnke
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors
Neurology,
June 13, 2006;
66(11):
1661 - 1667.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. T. Grier and T. Batchelor
Low-grade gliomas in adults.
Oncologist,
June 1, 2006;
11(6):
681 - 693.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Mohapatra, R. A. Betensky, E. R. Miller, B. Carey, L. D. Gaumont, D. A. Engler, and D. N. Louis
Glioma Test Array for Use with Formalin-Fixed, Paraffin-Embedded Tissue: Array Comparative Genomic Hybridization Correlates with Loss of Heterozygosity and Fluorescence in Situ Hybridization
J. Mol. Diagn.,
May 1, 2006;
8(2):
268 - 276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. E. Abrey, B. H. Childs, N. Paleologos, L. Kaminer, S. Rosenfeld, D. Salzman, J. L. Finlay, S. Gardner, K. Peterson, W. Hu, et al.
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up
Neuro-oncol,
April 1, 2006;
8(2):
183 - 188.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. F. Lang and M. R. Gilbert
Diffusely Infiltrative Low-Grade Gliomas in Adults
J. Clin. Oncol.,
March 10, 2006;
24(8):
1236 - 1245.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Jaeckle, K. V. Ballman, R. D. Rao, R. B. Jenkins, and J. C. Buckner
Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response
J. Clin. Oncol.,
March 10, 2006;
24(8):
1246 - 1252.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Hata, K. Yoshimoto, N. Yokoyama, M. Mizoguchi, T. Shono, Y. Guan, T. Tahira, Y. Kukita, K. Higasa, S. Nagata, et al.
Allelic Losses of Chromosome 10 in Glioma Tissues Detected by Quantitative Single-Strand Conformation Polymorphism Analysis
Clin. Chem.,
March 1, 2006;
52(3):
370 - 378.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. French, S. M.A. Swagemakers, J. H.A. Nagel, M. C.M. Kouwenhoven, E. Brouwer, P. van der Spek, T. M. Luider, J. M. Kros, M. J. van den Bent, and P. A. Sillevis Smitt
Gene Expression Profiles Associated with Treatment Response in Oligodendrogliomas
Cancer Res.,
December 15, 2005;
65(24):
11335 - 11344.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. W. Song, G. N. Fuller, H. Zheng, and W. Zhang
Inactivation of the Invasion Inhibitory Gene IIp45 by Alternative Splicing in Gliomas
Cancer Res.,
May 1, 2005;
65(9):
3562 - 3567.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Hong, A. Maunakea, P. Jun, A. W. Bollen, J. G. Hodgson, D. D. Goldenberg, W. A. Weiss, and J. F. Costello
Shared Epigenetic Mechanisms in Human and Mouse Gliomas Inactivate Expression of the Growth Suppressor SLC5A8
Cancer Res.,
May 1, 2005;
65(9):
3617 - 3623.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. G. Fisher and P. A. Buffler
Malignant Gliomas in 2005: Where to GO From Here?
JAMA,
February 2, 2005;
293(5):
615 - 617.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Cha, T. Tihan, F. Crawford, N. J. Fischbein, S. Chang, A. Bollen, S. J. Nelson, M. Prados, M. S. Berger, and W. P. Dillon
Differentiation of Low-Grade Oligodendrogliomas from Low-Grade Astrocytomas by Using Quantitative Blood-Volume Measurements Derived from Dynamic Susceptibility Contrast-Enhanced MR Imaging
AJNR Am. J. Neuroradiol.,
February 1, 2005;
26(2):
266 - 273.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. D. Voloschin, D. N. Louis, G. R. Cosgrove, and T. T. Batchelor
Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: Case study
Neuro-oncol,
January 1, 2005;
7(1):
97 - 100.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Korshunov, R. Sycheva, and A. Golanov
Molecular Stratification of Diagnostically Challenging High-Grade Gliomas Composed of Small Cells: The Utility of Fluorescence In situ Hybridization
Clin. Cancer Res.,
December 1, 2004;
10(23):
7820 - 7826.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. G. Cairncross
Imaging Molecular Signatures in Oligodendroglioma: Commentary on Walker et al., pages 7182-7191
Clin. Cancer Res.,
November 1, 2004;
10(21):
7109 - 7111.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Walker, D. G. du Plessis, D. Fildes, B. Haylock, D. Husband, M. D. Jenkinson, K. A. Joyce, J. Broome, K. Kopitski, J. Prosser, et al.
Correlation of Molecular Genetics with Molecular and Morphological Imaging in Gliomas with an Oligodendroglial Component
Clin. Cancer Res.,
November 1, 2004;
10(21):
7182 - 7191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. N. Eskandar, J. S. Loeffler, A. M. O'Neill, G. J. Hunter, and D. N. Louis
Case 33-2004 - A 34-Year-Old Man with a Seizure and a Frontal-Lobe Brain Lesion
N. Engl. J. Med.,
October 28, 2004;
351(18):
1875 - 1882.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Hoang-Xuan, L. Capelle, M. Kujas, S. Taillibert, H. Duffau, J. Lejeune, M. Polivka, E. Criniere, Y. Marie, K. Mokhtari, et al.
Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions
J. Clin. Oncol.,
August 1, 2004;
22(15):
3133 - 3138.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. N. Wiltshire, J. E. Herndon II, A. Lloyd, H. S. Friedman, D. D. Bigner, S. H. Bigner, and R. E. McLendon
Comparative Genomic Hybridization Analysis of Astrocytomas: Prognostic and Diagnostic Implications
J. Mol. Diagn.,
August 1, 2004;
6(3):
166 - 179.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
P. Leuraud, L. Taillandier, J. Medioni, L. Aguirre-Cruz, E. Criniere, Y. Marie, M. Kujas, J.-L. Golmard, A. Duprez, J.-Y. Delattre, et al.
Distinct Responses of Xenografted Gliomas to Different Alkylating Agents Are Related to Histology and Genetic Alterations
Cancer Res.,
July 1, 2004;
64(13):
4648 - 4653.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Megyesi, E. Kachur, D. H. Lee, M. C. Zlatescu, R. A. Betensky, P. A. Forsyth, Y. Okada, H. Sasaki, M. Mizoguchi, D. N. Louis, et al.
Imaging Correlates of Molecular Signatures in Oligodendrogliomas
Clin. Cancer Res.,
July 1, 2004;
10(13):
4303 - 4306.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Lebrun, D. Fontaine, A. Ramaioli, F. Vandenbos, S. Chanalet, M. Lonjon, J. F. Michiels, V. Bourg, P. Paquis, M. Chatel, et al.
Long-term outcome of oligodendrogliomas
Neurology,
May 25, 2004;
62(10):
1783 - 1787.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Chakravarti, G. Zhai, Y. Suzuki, S. Sarkesh, P. M. Black, A. Muzikansky, and J. S. Loeffler
The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas
J. Clin. Oncol.,
May 15, 2004;
22(10):
1926 - 1933.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Brat, W. F. Seiferheld, A. Perry, E. H. Hammond, K. J. Murray, A. R. Schulsinger, M. P. Mehta, and W. J. Curran
Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials
Neuro-oncol,
April 1, 2004;
6(2):
96 - 103.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Reardon, J. A. Quinn, J. N. Rich, S. Gururangan, J. Vredenburgh, J. H. Sampson, J. M. Provenzale, A. Walker, M. Badruddoja, S. Tourt-Uhlig, et al.
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma
Neuro-oncol,
April 1, 2004;
6(2):
134 - 144.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. K. Naugle, T. D. Duncan, and G. P. Grice
Oligoastrocytoma
RadioGraphics,
March 1, 2004;
24(2):
598 - 600.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Wang, K. M. Murphy, P. Kulesza, K. J. Hatanpaa, A. Olivi, A. Tufaro, Y. Erozan, W. H. Westra, P. C. Burger, and K. D. Berg
Molecular Diagnosis of Metastasizing Oligodendroglioma: A Case Report
J. Mol. Diagn.,
February 1, 2004;
6(1):
52 - 57.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. A. Brandes, U. Basso, F. Vastola, A. Tosoni, L. M. Pasetto, A. Jirillo, S. Lonardi, M. K. Paris, H. Koussis, S. Monfardini, et al.
Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study
Ann. Onc.,
December 1, 2003;
14(12):
1727 - 1731.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Hong, A. W. Bollen, and J. F. Costello
The Contribution of Genetic and Epigenetic Mechanisms to Gene Silencing in Oligodendrogliomas
Cancer Res.,
November 15, 2003;
63(22):
7600 - 7605.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Walker, D. G. du Plessis, K. A. Joyce, Y. Machell, J. Thomson-Hehir, S. A. Al Haddad, J. C. Broome, and P. C. Warnke
Phenotype versus Genotype in Gliomas Displaying Inter- or Intratumoral Histological Heterogeneity
Clin. Cancer Res.,
October 15, 2003;
9(13):
4841 - 4851.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Perry
Pathology of low-grade gliomas: An update of emerging concepts
Neuro-oncol,
July 1, 2003;
5(3):
168 - 178.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. van den Bent, O.-L. Chinot, and J. G. Cairncross
Recent developments in the molecular characterization and treatment of oligodendroglial tumors
Neuro-oncol,
April 1, 2003;
5(2):
128 - 138.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
W. A. Weiss, M. J. Burns, C. Hackett, K. Aldape, J. R. Hill, H. Kuriyama, N. Kuriyama, N. Milshteyn, T. Roberts, M. F. Wendland, et al.
Genetic Determinants of Malignancy in a Mouse Model for Oligodendroglioma
Cancer Res.,
April 1, 2003;
63(7):
1589 - 1595.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Buckner, D. Gesme Jr, J. R. O'Fallon, J. E. Hammack, S. Stafford, P. D. Brown, R. Hawkins, B. W. Scheithauer, B. J. Erickson, R. Levitt, et al.
Phase II Trial of Procarbazine, Lomustine, and Vincristine as Initial Therapy for Patients With Low-Grade Oligodendroglioma or Oligoastrocytoma: Efficacy and Associations With Chromosomal Abnormalities
J. Clin. Oncol.,
January 15, 2003;
21(2):
251 - 255.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Burton, K. R. Lamborn, B. G. Feuerstein, M. Prados, J. Scott, P. Forsyth, S. Passe, R. B. Jenkins, and K. D. Aldape
Genetic Aberrations Defined by Comparative Genomic Hybridization Distinguish Long-Term from Typical Survivors of Glioblastoma
Cancer Res.,
November 1, 2002;
62(21):
6205 - 6210.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Del Valle, S. Enam, C. Lara, C. Ortiz-Hidalgo, C. D. Katsetos, and K. Khalili
Detection of JC Polyomavirus DNA Sequences and Cellular Localization of T-Antigen and Agnoprotein in Oligodendrogliomas
Clin. Cancer Res.,
November 1, 2002;
8(11):
3332 - 3340.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Hartmann, L. Johnk, G. Kitange, Y. Wu, L. K. Ashworth, R. B. Jenkins, and D. N. Louis
Transcript Map of the 3.7-Mb D19S112-D19S246 Candidate Tumor Suppressor Region on the Long Arm of Chromosome 19
Cancer Res.,
July 15, 2002;
62(14):
4100 - 4108.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Mueller, C. Hartmann, A. Hoffmann, W. Lanksch, J. Kiwit, J. Tonn, J. Veelken, J. Schramm, M. Weller, O. D. Wiestler, et al.
Genetic Signature of Oligoastrocytomas Correlates with Tumor Location and Denotes Distinct Molecular Subsets
Am. J. Pathol.,
July 1, 2002;
161(1):
313 - 319.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Chakravarti, E. Noll, P. McL. Black, D. F. Finkelstein, D. M. Finkelstein, N. J. Dyson, and J. S. Loeffler
Quantitatively Determined Survivin Expression Levels Are of Prognostic Value in Human Gliomas
J. Clin. Oncol.,
February 15, 2002;
20(4):
1063 - 1068.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Burton, K. R. Lamborn, P. Forsyth, J. Scott, J. O'Campo, J. Uyehara-Lock, M. Prados, M. Berger, S. Passe, J. Uhm, et al.
Aberrant p53, mdm2, and Proliferation Differ in Glioblastomas from Long-Term Compared with Typical Survivors1
Clin. Cancer Res.,
January 1, 2002;
8(1):
180 - 187.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ueki, R. Nishikawa, Y. Nakazato, T. Hirose, J. Hirato, N. Funada, T. Fujimaki, S. Hojo, O. Kubo, T. Ide, et al.
Correlation of Histology and Molecular Genetic Analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 Astrocytic and Oligodendroglial Tumors
Clin. Cancer Res.,
January 1, 2002;
8(1):
196 - 201.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Hoang-Xuan, J. He, S. Huguet, K. Mokhtari, Y. Marie, M. Kujas, P. Leuraud, L. Capelle, J. Y. Delattre, J. Poirier, et al.
Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression
Neurology,
October 9, 2001;
57(7):
1278 - 1281.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kunwar, G. Mohapatra, A. Bollen, K. R. Lamborn, M. Prados, and B. G. Feuerstein
Genetic Subgroups of Anaplastic Astrocytomas Correlate with Patient Age and Survival
Cancer Res.,
October 1, 2001;
61(20):
7683 - 7688.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Zlatescu, A. TehraniYazdi, H. Sasaki, J. F. Megyesi, R. A. Betensky, D. N. Louis, and J. G. Cairncross
Tumor Location and Growth Pattern Correlate with Genetic Signature in Oligodendroglial Neoplasms
Cancer Res.,
September 1, 2001;
61(18):
6713 - 6715.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. N. Louis, E. C. Holland, and J. G. Cairncross
Glioma Classification : A Molecular Reappraisal
Am. J. Pathol.,
September 1, 2001;
159(3):
779 - 786.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Smith, I. Tachibana, S. M. Passe, B. K. Huntley, T. J. Borell, N. Iturria, J. R. O'Fallon, P. L. Schaefer, B. W. Scheithauer, C. D. James, et al.
PTEN Mutation, EGFR Amplification, and Outcome in Patients With Anaplastic Astrocytoma and Glioblastoma Multiforme
J Natl Cancer Inst,
August 15, 2001;
93(16):
1246 - 1256.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Chakravarti, M. A. Delaney, E. Noll, P. McL. Black, J. S. Loeffler, A. Muzikansky, and N. J. Dyson
Prognostic and Pathologic Significance of Quantitative Protein Expression Profiling in Human Gliomas
Clin. Cancer Res.,
August 1, 2001;
7(8):
2387 - 2395.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O.-L. Chinot, S. Honore, H. Dufour, M. Barrie, D. Figarella-Branger, X. Muracciole, D. Braguer, P.-M. Martin, and F. Grisoli
Safety and Efficacy of Temozolomide in Patients With Recurrent Anaplastic Oligodendrogliomas After Standard Radiotherapy and Chemotherapy
J. Clin. Oncol.,
May 1, 2001;
19(9):
2449 - 2455.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Caggana, J. Kilgallen, J. M. Conroy, J. K. Wiencke, K. T. Kelsey, R. Miike, P. Chen, and M. R. Wrensch
Associations Between ERCC2 Polymorphisms and Gliomas
Cancer Epidemiol. Biomarkers Prev.,
April 1, 2001;
10(4):
355 - 360.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
Y. Ino, R. A. Betensky, M. C. Zlatescu, H. Sasaki, D. R. Macdonald, A. O. Stemmer-Rachamimov, D. A. Ramsay, J. G. Cairncross, and D. N. Louis
Molecular Subtypes of Anaplastic Oligodendroglioma: Implications for Patient Management at Diagnosis
Clin. Cancer Res.,
April 1, 2001;
7(4):
839 - 845.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. M. Nigro, M. A. Takahashi, D. G. Ginzinger, M. Law, S. Passe, R. B. Jenkins, and K. Aldape
Detection of 1p and 19q Loss in Oligodendroglioma by Quantitative Microsatellite Analysis, a Real-Time Quantitative Polymerase Chain Reaction Assay
Am. J. Pathol.,
April 1, 2001;
158(4):
1253 - 1262.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Watson, A. Perry, V. Budhjara, C. Hicks, W. D. Shannon, and K. M. Rich
Gene Expression Profiling with Oligonucleotide Microarrays Distinguishes World Health Organization Grade of Oligodendrogliomas
Cancer Res.,
March 1, 2001;
61(5):
1825 - 1829.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. M. MARKERT, C. M. FULLER, G. Y. GILLESPIE, J. K. BUBIEN, L. A. MCLEAN, R. L. HONG, K. LEE, S. R. GULLANS, T. B. MAPSTONE, and D. J. BENOS
Differential gene expression profiling in human brain tumors
Physiol Genomics,
February 7, 2001;
5(1):
21 - 33.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. DeAngelis
Brain Tumors
N. Engl. J. Med.,
January 11, 2001;
344(2):
114 - 123.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Huang, S. Colella, M. Kurrer, Y. Yonekawa, P. Kleihues, and H. Ohgaki
Gene Expression Profiling of Low-Grade Diffuse Astrocytomas by cDNA Arrays
Cancer Res.,
December 1, 2000;
60(24):
6868 - 6874.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
K. D. Geiger, P. Stoldt, W. Schlote, and A. Derouiche
Ezrin Immunoreactivity Is Associated with Increasing Malignancy of Astrocytic Tumors but Is Absent in Oligodendrogliomas
Am. J. Pathol.,
December 1, 2000;
157(6):
1785 - 1793.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|